Calendario›MOLN›MP0250
MP0250
First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
Ensayo de MOLECULAR PARTNERS AG en Neoplasias.
Más ensayos de: Neoplasias.
- Fase
- Fase 1/2
- Estado
- Completado
- Participantes
- 58
- Centros
- 4
- Fin del objetivo primario
- feb 2018
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en jul 2014.
Qué mide
Proportion of patients with dose limiting toxicities (From the Day 0 (first infusion) up to 35 days) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis research study is looking at a new DARPin® drug candidate, called MP0250. There is evidence from preclinical studies that MP0250 may be effective in the treatment of cancer. This is the first study of MP0250 in humans and its main purpose is to test its safety and tolerability in patients with cancer. This study will also examine how the drug is changed by and removed from the body and look for indicators that the drug may be effective against cancer. This study will test several different dose levels of the study drug to determine the safety and tolerability profile of the drug.
Más ensayos de MOLN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| [212Pb]Pb-MP0712 | Fase 1/2 | Reclutando pacientes | sep 2028 (prevista) |
| MP0533 | Fase 1 | Completado | may 2026 (real) |
| MP0317 | Fase 1 | Interrumpido | ene 2024 (real) |
| MP0310 | Fase 1 | Completado | jun 2022 (real) |
| Ensovibep | Fase 1 | Interrumpido | ene 2022 (real) |
| MP0274 | Fase 1 | Completado | dic 2021 (real) |
Todos los de MOLN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT02194426), actualizada en ago 2019.